- Previous Close
2.1500 - Open
2.1900 - Bid 1.6100 x 200
- Ask 2.5800 x 200
- Day's Range
2.0000 - 2.2800 - 52 Week Range
0.4320 - 16.6300 - Volume
624,320 - Avg. Volume
2,257,747 - Market Cap (intraday)
3.921M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-32.1600 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
www.painreform.com7
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PRFX
View More
Performance Overview: PRFX
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRFX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRFX
View MoreValuation Measures
Market Cap
3.92M
Enterprise Value
-295.20k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-195.07%
Return on Equity (ttm)
-716.67%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.67M
Diluted EPS (ttm)
-32.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
2.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.93M